Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 18/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540542 | 0.78 | LMNA (0.31) | POLBAPEX1 | |
| SCHEMBL974515 | 0.77 | SCN9A (0.43) | POLBAPEX1SCN9ACYP2C19 | |
| SCHEMBL973560 | 0.75 | SCN9A (0.34) | POLBAPEX1SCN9ACYP2C19 | |
| SCHEMBL3542443 | 0.71 | SCN9A (0.32) | POLBAPEX1SCN9A | |
| SCHEMBL9051631 | 0.69 | GAA (0.40) | POLBAPEX1CYP2C19 | |
| SCHEMBL10471483 | 0.69 | LMNA (0.40) | POLBAPEX1CYP2C19 | |
| SCHEMBL9492204 | 0.69 | KEAP1 (0.38) | POLBAPEX1 | |
| SCHEMBL9419230 | 0.68 | POLB (0.33) | POLBAPEX1 | |
| SCHEMBL10913911 | 0.66 | TSHR (0.41) | CYP2C19 | |
| SCHEMBL10913907 | 0.66 | MAPT (0.38) | POLBAPEX1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737275-B2 | Method for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| EP-1692115-B1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | disclosed |
| EP-1692115-A1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005054208-A1 | METHOD FOR PRODUCING 3-PHENYL(THIO)URACILS AND 3-PHENYLDITHIOURACILS | BASF AKTIENGESELLSCHAFT (DE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293520-A1 | Mehtod for producing 3-phenyl(thio)uracils and 3-phenyldithiouracils | HPRT1, TH, METTL3 | POLB 2308/4885APEX1 368/4885SCN9A 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.